21st Austria weekly - Marinomed (09/06/2025)

Marinomed: Austrian science-based biotech company Marinomed Biotech AG has signed a binding term sheet with a Swiss pharmaceutical company for the development and marketing of Budesolv for the Swiss market. The new partner has been granted exclusive rights to sell and distribute Budesolv under its own brand. The deal includes the final development steps that are necessary for filing the marketing authorization in Switzerland. Marinomed is eligible to receive undisclosed upfront and milestone payments as well as royalties on sales. Marinomed retains all rights outside the territory and has the right to use the dossier compiled for Switzerland outside the territory. Andreas Grassauer, CEO of Marinomed comments: “We are confident that this deal is the first trigger for several other partnerships to come. We are convinced that a registration in Switzerland will enable opportunities in a series of other markets abroad.”
Marinomed Biotech: weekly performance: -2.63%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (09/06/2025)

Christian Drastil: Wiener Börse Plausch

kapitalmarkt-stimme.at daily voice 189/365: Markus Marterbauer meets Christoph Boschan im Börsianer (Tuesday Tipp Third Party)

Bildnachweis

1. 21st Austria Weekly

Aktien auf dem Radar:Agrana, Kapsch TrafficCom, Amag, Austriacard Holdings AG, Semperit, EuroTeleSites AG, AT&S, Zumtobel, CPI Europe AG, Frequentis, EVN, OMV, Flughafen Wien, Gurktaler AG Stamm, Heid AG, Linz Textil Holding, voestalpine, CA Immo, Palfinger, Oberbank AG Stamm, Pierer Mobility, Österreichische Post, Telekom Austria, Uniqa, VIG.

Random Partner

---

Verbund
Verbund ist Österreichs führendes Stromunternehmen und einer der größten Stromerzeuger aus Wasserkraft in Europa. Mit Tochterunternehmen und Partnern ist Verbund von der Stromerzeugung über den Transport bis zum internationalen Handel und Vertrieb aktiv. Seit 1988 ist Verbund an der Börse.

>> Besuchen Sie 60 weitere Partner auf boerse-social.com/partner